Digene Piloting DTC Ads In Effort To Capture HPV Test Market Share
This article was originally published in The Gray Sheet
Executive Summary
Digene expects to increase its 9% share of the U.S. human papillomavirus (HPV) testing market - estimated at 35 mil. tests annually - by 1%-1.5% per quarter during fiscal 2005
You may also be interested in...
Cervical Cancer Screening Initiatives Sought By Women In Government
States should mandate coverage for Digene's DNAwithPap human papillomavirus test and other FDA-approved cervical cancer screening technologies, according to a Women in Government report
Digene Stock Rebound Could Continue In 2005; OTC Index Ahead 23%
Digene's increased focus on physician detailing for its DNAwithPap human papillomavirus test, coupled with plans for consumer advertising, could allow the firm to exceed recently revised growth expectations
Cervical Cancer Screening Initiatives Sought By Women In Government
States should mandate coverage for Digene's DNAwithPap human papillomavirus test and other FDA-approved cervical cancer screening technologies, according to a Women in Government report